Footnotes

• Members of the Genval Workshop Group: Lars Agréus (Öregrund, Sweden); David Armstrong (Hamilton, Ontario, Canada); Gil Barbezat (Salford, UK); John Calam (London, UK); Francesco Carelli (Milan, Italy); Meinhard Classen (München, Germany); Ken De Vault (Jacksonville, Florida, USA); Jean Paul Galmiche (Nantes, France); Richard Holloway (Adelaide, Australia); Michio Hongo (Sendai, Japan); Jürgen Hotz (Celle, Germany); Terje Johannessen (Trondheim, Norway); Folke Johnsson (Lund, Sweden); Hans-Rudolf Koelz (Zürich, Switzerland); S K Lam (Hong Kong); Mark Lane (Auckland, New Zealand); Lars Lundell (Göteborg, Sweden); Peter Malfertheiner (Magdeburg, Germany); Paul Moayyedi (Leeds, UK); Wolfgang Rösch (Frankfurt, Germany); Marc Silverstein (Charleston, South Carolina, USA); Amnon Sonnenberg (Albuquerque, New Mexico, USA); Vincenzo Stanghellini (Bologna, Italy); Ian Wallace (Auckland, New Zealand); Anthony Watson (London, UK; Yin Thing Phee (Selangor Darul Ehsan, Malaysia).    Publication of this supplement has been made possible by an educational grant from Astra.

• Abbreviations used in this report:

  GORD

  gastro-oesophageal reflux disease

  PPI

  proton pump inhibitor

  SF-36

  short form 36

  PGWB

  psychological general well being

  GSRS

  gastrointestinal symptom rating scale

  H₂RA

  H₂ receptor antagonist